Allurion Technologies, Inc. · OTC:ALUR
Allurion Technologies — SPAC Merger (June 2023)
25 slides from Allurion Technologies's SPAC merger presentation, Jun 9, 2023
Slide 1: Allurion
Allurion
Slide 2: Disclaimer: Forward-Looking Statements
Disclaimer Forward-Looking Statements Certain statements, estimates, targets and projections in this presentation may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Actual results may differ
Slide 3: We have one goal: End Obesity
We have one goal: End Obesity
Slide 4: Allurion Aims to Solve One of the Biggest Problems in Healthcare
Allurion Aims to Solve One of the Biggest Problems in Healthcare, is Growing at an 4 Exceptional Rate, and is Nearing Several Multi-Billion Dollar Catalysts Obesity is one of the biggest unmet medical needs in the world and new GLP-1 drugs 1 1 have unlocked a $50B+ revenue opportunity Allurion deliv
Slide 5: Allurion Is Going Public With Wind At Its Sails
Allurion Is Going Public With Wind At Its Sails Key Milestones Record High Revenue FDA Trial Launch No safety signals Enrollment at 75% and ahead of schedule 100,000+ $64 patients in 50+ countries SAB Additions 2.5 million $38 app sessions in 2022 Regina Bob Barzilay Langer $20 78% $13 gross margin
Slide 6: The Problem
The Problem Allurion PROGRAM
Slide 7: Why We Believe Other Weight Loss Innovations Fail
Why We Believe Other Weight Loss Innovations Fail 7 Poor High Poor Limited Flawed Go- Experience Risks Economics Channels To-Market Execution Lack of remote Invasive procedures Bariatric surgery Most providers lack Previous companies patient monitoring are inherently risky is estimated to be infrast
Slide 8: The Time is Now: GLP-1 Drugs Created Unprecedented Interest in Weight Loss
The Time is Now: GLP-1 Drugs Created Unprecedented Interest in Weight Loss and Unlocked a $50 Billion Revenue Opportunity Obesity: $50B+ Revenue Market by 2030 GLP-1s Made Obesity Mainstream GLP-1 Drug Approvals 2015 2017 2019 2021 2022 *Sources: Morgan Stanley, “Unlocking the Obesity Challenge: a >
Slide 9: GLP-1 Drugs Face Several Challenges Allurion Can Capitalize Upon
GLP-1 Drugs Face Several Challenges Allurion Can Capitalize Upon 9 Poor High High Weight Experience Risks Costs Re-Gain Weekly injection Thyroid cancer $1,000 per month Weight is re- associated with with limited gained quickly if 2 long-term use insurance drugs are Real-world drop- 4 5 coverage stop
Slide 10: Our Solution
Our Solution Allurion PROGRAM
Slide 11: The Allurion Program Combines a Medical Device, Digital Therapeutic, and Behavior Change Program
The Allurion Program Combines a Revolutionary Medical Device, Cutting-Edge 11 Digital Therapeutic, and Behavior Change Program “Honeymoon from Hunger” ® The Allurion Balloon Allurion Iris AI Platform Behavior Change Program The world’s first and only AI-powered digital therapeutic and Clinically pro
Slide 12: AI in Action: The Success Predictor
AI in Action: The Success Predictor 12 Proprietary algorithm trained on millions of data points from over 7,000 Allurion patients Identifies “off-track” patients as early as 20 days into the Program Enables providers to intervene sooner and get patients back on track © 2021 ALLURION TECHNOLOGIES - P
Slide 13: Meet Coach Iris: A 24/7 Weight Loss Coach Powered by ChatGPT
Meet Coach Iris: Coming 2H-23 13 A 24/7 Weight Loss Coach Powered by ChatGPT Fine-Tuned to the Allurion Behavior Change Program Key Features 24/7 weight loss coach Powered by ChatGPT Trained on the proprietary Allurion Behavior Change Program and millions of data points on weight, activity, sleep, a
Slide 14: Using Generative AI, Coaching Can Be Fully Personalized Across 50 Markets
Using Generative AI, Coaching Can Be Fully Personalized Across 50 Markets 14 B2C Vision B2B Vision Build an infinite army of 24/7 Create custom, 24/7 weight loss weight loss coaches personalized coaches tailored to individual to each consumer and localized to physician practices that augment each of
Slide 15: Allurion Patients Achieve Pounds of Life-Changing Weight Loss and Keep 95% of it Off
Allurion Patients Achieve 30 Pounds of Life-Changing Weight Loss on Average and 15 Keep 95% of it Off at 1-Year Diabetes Remission Weight Loss Weight Maintenance 95% -1.5 at 12 HbA1c months 30 pounds with 1 balloon at 4 months -1.5 in HbA1c in diabetics 30 pounds 29 pounds -1.1 at 4 months at 12 mon
Slide 16: New Clinical Studies Report 15%+ Weight Loss
New Clinical Studies Report 15%+ Weight Loss 16 Boosting Long-Term Balloon + Drug: Results A New Paradigm 232 patient study with 1- 181 patient study combining year follow-up Allurion Balloon with GLP-1 weight loss drug Allurion Balloon therapy for the first 4 months with 19% total body weight ongoi
Slide 17: Future Opportunities
Future Opportunities Allurion PROGRAM
Slide 18: Our 3-Year Strategy
Our 3-Year Strategy 18 Expand revenues in existing markets Launch in new markets Expand our platform to engage patients for a lifetime © 2021 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION – CONFIDENTIAL
Slide 19: Expand Revenues in Existing Markets
Expand Revenues in Existing Markets 19 Even at 100% CAGR, our TAM is still untapped 80-200+% CAGR High growth across all <0.2% penetration rate globally in top direct markets regions globally France Spain UK 5000 0.10% 8000 0.30% 3500 0.06% 4500 0.09% 7000 3000 0.25% 0.05% 4000 0.08% 6000 2500 3500
Slide 20: Anticipated Launches in High Potential New Markets
Anticipated Launches in High Potential New Markets* 20 Future Market Openings Will Drive Continued Growth 700M 1.1B 1.3B 2 Billion Across 44 countries 2021 2022 2023 2024+ Source: Allurion Market Research. *Values denote estimated number of individuals with BMI 25+ in launched territories. Only sele
Slide 21: IDE for AUDACITY Trial Has Been Approved by FDA
21 IDE for AUDACITY Trial Has Been Approved by FDA Enrollment begun in May 2022 W0 W16 W24 W40 W48 Balloon 1 Break Balloon 2 Break Moderate Intensity Lifestyle Therapy Treatment Group (n = 250) Moderate Intensity Lifestyle Therapy Control Group (n = 250) Co-Primary 50% responder rate 3.0% total body
Slide 22: Sequential Use of Allurion Balloon
Sequential Use of Allurion Balloon 22 In a study of 42 patients, sequential balloon use led to an average weight loss of 22kg at 1-year Balloon #1 Break Balloon #2 Responder Rate 0.0 % of Patients %TBWL ≥5% 100% -5.0 -14% 97.6% ≥10% -10.0 +2% ≥20% 64.7% -15.0 -10% 26.1% ≥30% -20.0 -23% -25.0 % Total
Slide 23: Allurion is Building an AI-Powered, Full-Stack Weight Loss Platform
Allurion is Building an AI-Powered, Full-Stack Weight Loss Platform 23 AI-powered Coaching and RPM BALLOON AI-powered AI-powered Treatment Treatment Selection Pathing PATIENT MEDICATION SURGERY
Slide 24: Key Highlights
Key Highlights 24 Strong Competitive Moat with Large Addressable Market with 1 4 Broad Patent Coverage Creates a tailwinds created by GLP-1s High Barrier to Entry Going Public with Seasoned Fast and Sustainable Weight Loss 2 5 Experience Powered by AI Strategic and Financial Partners Regulatory Appr
Slide 25: Allurion
Allurion